Overview A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs) Status: Active, not recruiting Trial end date: 2024-12-30 Target enrollment: Participant gender: Summary to Assess the Pharmacokinetic Properties of VeraCept™ Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women Phase: Phase 3 Details Lead Sponsor: Sebela Pharmaceuticals Inc.Collaborator: Synteract, Inc.